LL-K8-22 is a potent, selective, and durable PROTAC CDK8-cyclin C dual degrader, exhibiting DC50 values of 2.52 and 2.64 μM respectively. It effectively suppresses STAT1 Ser 727 phosphorylation and inhibits E2F- and MYC-driven carcinogenic transcriptional programs. This compound is suitable for research pertaining to triple-negative breast cancer (TNBC).
- Functions as a potent, selective, and durable PROTAC CDK8-cyclin C dual degrader.
- Suppresses STAT1 Ser 727 phosphorylation.
- Inhibits E2F- and MYC-driven carcinogenic transcriptional programs.
- Applicable for triple-negative breast cancer (TNBC) research.
- Suppresses tumor cell proliferation in vitro.
- Selectively degrades CDK8 without affecting CDK19 or other cyclin proteins, except cyclin C.